A
Ajita V. Singh
Researcher at Harvard University
Publications - 22
Citations - 1940
Ajita V. Singh is an academic researcher from Harvard University. The author has contributed to research in topics: Bortezomib & Proteasome inhibitor. The author has an hindex of 14, co-authored 22 publications receiving 1845 citations. Previous affiliations of Ajita V. Singh include University of Pittsburgh & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.
TL;DR: This study reports that Sulforaphane inhibited proliferation of cultured PC-3 human prostate cancer cells by inducing apoptosis that was characterized by appearance of cells with sub-G0/G1 DNA content, formation of cytoplasmic histone associated DNA fragments and cleavage of poly(ADP-ribose)polymerase (PARP).
Journal ArticleDOI
Sulforaphane-induced G2/M Phase Cell Cycle Arrest Involves Checkpoint Kinase 2-mediated Phosphorylation of Cell Division Cycle 25C
Shivendra V. Singh,Anna Herman-Antosiewicz,Ajita V. Singh,Karen L. Lew,Sanjay K. Srivastava,Ravindra Kamath,Kevin D. Brown,Lin Zhang,R. Baskaran +8 more
TL;DR: It is demonstrated that SFN treatment causes an irreversible arrest in the G2/M phase of the cell cycle, and activation of checkpoint kinase 2 (Chk2) plays a major role in irreversible G 2/M arrest by SFN.
Journal ArticleDOI
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Dharminder Chauhan,Ajita V. Singh,Mohan Brahmandam,Ruben D. Carrasco,Madhavi Bandi,Teru Hideshima,Giada Bianchi,Klaus Podar,Yu-Tzu Tai,Constantine S. Mitsiades,Noopur Raje,David L. Jaye,Shaji Kumar,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +15 more
TL;DR: Targeting pDC-MM interactions as a therapeutic strategy to overcome drug resistance in MM is validates targeting toll-like receptors with CpG oligodeoxynucleotides.
Journal ArticleDOI
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
Dharminder Chauhan,Ajita V. Singh,Mohan Brahmandam,Klaus Podar,Teru Hideshima,Paul G. Richardson,Nikhil C. Munshi,Michael A. Palladino,Kenneth C. Anderson +8 more
TL;DR: It is demonstrated that combining NPI-0052 and bortezomb induces synergistic anti-MM activity both in vitro using MM cell lines or patient CD138(+) MM cells and in vivo in a human plasmacytoma xenograft mouse model.
Journal ArticleDOI
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
Dharminder Chauhan,Ajita V. Singh,Monette Aujay,Christopher J. Kirk,Madhavi Bandi,Bryan Ciccarelli,Noopur Raje,Paul G. Richardson,Kenneth C. Anderson +8 more
TL;DR: It is shown that the novel proteasome inhibitor ONX 0912, a tripeptide epoxyketone, inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies.